Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

M. Zibelman; L. J. Goldstein

doi:10.1016/j.breastdis.2013.07.034

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

M. Zibelman, L. J. Goldstein

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	269-270
Number of pages	2
Journal	Breast Diseases
Volume	24
Issue number	3
DOIs	https://doi.org/10.1016/j.breastdis.2013.07.034
State	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breastdis.2013.07.034

Fingerprint

Dive into the research topics of 'Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer'. Together they form a unique fingerprint.

Cite this

Zibelman, M., & Goldstein, L. J. (2013). Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. Breast Diseases, 24(3), 269-270. https://doi.org/10.1016/j.breastdis.2013.07.034

Zibelman, M. ; Goldstein, L. J. / Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. In: Breast Diseases. 2013 ; Vol. 24, No. 3. pp. 269-270.

@article{af4325ce0748468bbbdd655ef48b91b9,

title = "Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer",

author = "M. Zibelman and Goldstein, {L. J.}",

year = "2013",

doi = "10.1016/j.breastdis.2013.07.034",

language = "English",

volume = "24",

pages = "269--270",

journal = "Breast Diseases",

issn = "1043-321X",

publisher = "Academic Press Inc.",

number = "3",

}

Zibelman, M & Goldstein, LJ 2013, 'Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer', Breast Diseases, vol. 24, no. 3, pp. 269-270. https://doi.org/10.1016/j.breastdis.2013.07.034

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. / Zibelman, M.; Goldstein, L. J.
In: Breast Diseases, Vol. 24, No. 3, 2013, p. 269-270.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

AU - Zibelman, M.

AU - Goldstein, L. J.

PY - 2013

Y1 - 2013

UR - http://www.scopus.com/inward/record.url?scp=84888249121&partnerID=8YFLogxK

U2 - 10.1016/j.breastdis.2013.07.034

DO - 10.1016/j.breastdis.2013.07.034

M3 - Comment/debate

AN - SCOPUS:84888249121

SN - 1043-321X

VL - 24

SP - 269

EP - 270

JO - Breast Diseases

JF - Breast Diseases

IS - 3

ER -

Zibelman M, Goldstein LJ. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. Breast Diseases. 2013;24(3):269-270. doi: 10.1016/j.breastdis.2013.07.034

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this